Thorsteinn Loftsson1, Marcus E Brewster. 1. Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata, Reykjavik, Iceland. thorstlo@hi.is
Abstract
OBJECTIVES: Cyclodextrins are useful solubilizing excipients that have gained currency in the formulator's armamentarium based on their ability to temporarily camouflage undesirable physicochemical properties. In this context cyclodextrins can increase oral bioavailability, stabilize compounds to chemical and enzymatic degradation and can affect permeability through biological membranes under certain circumstances. This latter property is examined herein as a function of the published literature as well as work completed in our laboratories. KEY FINDINGS: Cyclodextrins can increase the uptake of drugs through biological barriers if the limiting barrier component is the unstirred water layer (UWL) that exists between the membrane and bulk water. This means that cyclodextrins are most useful when they interact with lipophiles in systems where such an UWL is present and contributes significantly to the barrier properties of the membrane. Furthermore, these principles are used to direct the optimal formulation of drugs in cyclodextrins. A second related critical success factor in the formulation of cyclodextrin-based drug product is an understanding of the kinetics and thermodynamics of complexation and the need to optimize the cyclodextrin amount and drug-to-cyclodextrin ratios. Drug formulations, especially those targeting compartments associated with limited dissolution (i.e. the eye, subcutaneous space, etc.), should be carefully designed such that the thermodynamic activity of the drug in the formulation is optimal meaning that there is sufficient cyclodextrin to solubilize the drug but not more than that. Increasing the cyclodextrin concentration decreases the formulation 'push' and may reduce the bioavailability of the system. CONCLUSIONS: A mechanism-based understanding of cyclodextrin complexation is essential for the appropriate formulation of contemporary drug candidates.
OBJECTIVES:Cyclodextrins are useful solubilizing excipients that have gained currency in the formulator's armamentarium based on their ability to temporarily camouflage undesirable physicochemical properties. In this context cyclodextrins can increase oral bioavailability, stabilize compounds to chemical and enzymatic degradation and can affect permeability through biological membranes under certain circumstances. This latter property is examined herein as a function of the published literature as well as work completed in our laboratories. KEY FINDINGS:Cyclodextrins can increase the uptake of drugs through biological barriers if the limiting barrier component is the unstirred water layer (UWL) that exists between the membrane and bulk water. This means that cyclodextrins are most useful when they interact with lipophiles in systems where such an UWL is present and contributes significantly to the barrier properties of the membrane. Furthermore, these principles are used to direct the optimal formulation of drugs in cyclodextrins. A second related critical success factor in the formulation of cyclodextrin-based drug product is an understanding of the kinetics and thermodynamics of complexation and the need to optimize the cyclodextrin amount and drug-to-cyclodextrin ratios. Drug formulations, especially those targeting compartments associated with limited dissolution (i.e. the eye, subcutaneous space, etc.), should be carefully designed such that the thermodynamic activity of the drug in the formulation is optimal meaning that there is sufficient cyclodextrin to solubilize the drug but not more than that. Increasing the cyclodextrin concentration decreases the formulation 'push' and may reduce the bioavailability of the system. CONCLUSIONS: A mechanism-based understanding of cyclodextrin complexation is essential for the appropriate formulation of contemporary drug candidates.
Authors: Ana Cláudia Santos; Diana Costa; Laura Ferreira; Catarina Guerra; Miguel Pereira-Silva; Irina Pereira; Diana Peixoto; Nuno R Ferreira; Francisco Veiga Journal: Drug Deliv Transl Res Date: 2021-02 Impact factor: 4.617
Authors: Jos Bloemers; Kim van Rooij; Leo de Leede; Henderik W Frijlink; Hans P F Koppeschaar; Berend Olivier; Adriaan Tuiten Journal: Br J Clin Pharmacol Date: 2016-03-07 Impact factor: 4.335
Authors: Pedro P G Guimaraes; Mingchee Tan; Tuomas Tammela; Katherine Wu; Amanda Chung; Matthias Oberli; Karin Wang; Roman Spektor; Rachel S Riley; Celso T R Viana; Tyler Jacks; Robert Langer; Michael J Mitchell Journal: J Control Release Date: 2018-10-02 Impact factor: 9.776
Authors: Sahar Awwad; Abeer H A Mohamed Ahmed; Garima Sharma; Jacob S Heng; Peng T Khaw; Steve Brocchini; Alastair Lockwood Journal: Br J Pharmacol Date: 2017-10-10 Impact factor: 8.739